Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS3887699 A
Type de publicationOctroi
Date de publication3 juin 1975
Date de dépôt29 déc. 1970
Date de priorité24 mars 1969
Numéro de publicationUS 3887699 A, US 3887699A, US-A-3887699, US3887699 A, US3887699A
InventeursYolles Seymour
Cessionnaire d'origineYolles Seymour
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Biodegradable polymeric article for dispensing drugs
US 3887699 A
Résumé
An article for dispensing drugs is disclosed which is formed from a biodegradable polymeric material and a drug. The drug is intimately dispersed throughout the polymer and the combination is formed into a solid, shaped article which controllably dispenses the drug.
Images(1)
Previous page
Next page
Description  (Le texte OCR peut contenir des erreurs.)

United States Patent [191 Yolles 1 June 3, 1975 1 1 BIODEGRADABLE POLYMERIC ARTICLE FOR DISPENSING DRUGS [2]] Appl. No.: 102,431

Related 1.1.8. Application Data [63] Continuation-impart of Ser. No. 809,946, March 24,

1969, abandoned.

[52] US. Cl. 424/19; 128/260; 424/20; 424/22; 424/32; 424/78 [51] Int. Cl A6lk 27/12 [58] Field of Search 128/260, 335.5 130; 424/1416, 19,22, 28, 78, 32

[56] References Cited UNlTED STATES PATENTS 2,625,158 l/1953 Lee et a1 128/260 3,297,033 10/1967 Schmitt et a1 1 128/3355 3,435,008 3/1969 Schmitt et a1 260/783 3,499,445 3/1970 Reed 128/260 3,545,439 12/1970 Duncan 128/260 3,565,991 2/1971 Short 424/243 3,618,213 11/1971 Shepherd et a1 32/2 3,625,214 12/1971 Higuchi 128/260 3,636,956 1/1972 Schneider 128/3355 R26,963 10/1970 Hardy 424/89 OTHER PUBLICATIONS Rudel et a1. Fertility & Sterility 18;219-222 (1967) Hormonal Fertility Control A Working Hypothesis For Population Control" Kincl et a1. J. Reprod. Fertil. 10:105-113 (1965) Antifertility Activity of Various Steroids in the Female Rat" Primary Examiner-Shep K. Rose {57] ABSTRACT An article for dispensing drugs is disclosed which is formed from a biodegradable polymeric material and a drug. The drug is intimately dispersed throughout the polymer and the combination is formed into a solid, shaped article which controllably dispenses the drug.

9 Claims, 5 Drawing Figures PATENTED JUH 3 ms RAT H RAT E RAT B //V VE/V TOR ATTORNEY,

SEYMOUR YOLZES TIME IN DAYS TIMED RELEASE OFACTIVE INGREDIENT FIG [I'D FROM RATS FIG. [[0

BIODEGRADABLE POLYMERIC ARTICLE FOR DISPENSING DRUGS CROSS REFERENCE TO RELATED APPLICATIONS This application is a continuation-in-part of Yolles. Ser. No. 809.946. filed Mar. 24. 1969 now abandoned.

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates broadly to the controlled release of drugs to the bloodstream of mammals and more particularly to a shaped article formed from a biodegradable polymer which contains a drug so that the article is suitable for implantation in a mammal to controllably release the drug.

2. Description of the Prior Art Medical science has long recognized the need for methods to controllably release therapeutic agents and other drugs to the blood stream of patients. Recently. a great deal of research has been initiated in attempting to find new release systems to fulfill this need. Several such systems have been recommended.

One common method for obtaining controlled release is to envelop the active substance with coatings which are attacked by digestive juices in the stomach. This technique has been widely used recently for timerelease analgesics. There are some problems with this method. however. such as: (l it is difficult to obtain the proper distribution of coating thicknesses to give the desired release; and (2) the sojourn time of the coated agent in the digestive tract is relatively short. thereby making this method unsuitable for longterm release.

Another method of obtaining controlled release is to mix the active substance with various binders such as fats. waxes. and natural or synthetic polymers to slow down release. Many of the binders. however. are unsuitable for use with many drugs. Furthermore. these combinations of binders and drugs tend to disperse quickly after they enter the body due to the binder's solubility in body fluids. the washing effect of the body fluids and/or the attack of digestive juices. After the binder has been so dispersed. all control over the release of the drug is lost.

Other researchers have even suggested that drugs be chemically modified to affect their release and absorption into the bloodstream. The degree of difficulty of this method for obtaining controlled release is clear.

More recently. the possibility of somehow incorporating drugs into polymeric materials to control drug release has been considered. Thus Furuse et al.. U.S. Pat. No. 3.5 l4.5 l 7. teach that suppositories containing spermicidal agents can be formed by blending the agents with low molecular weight polyethylene glycols; Hill. U.S. Pat. No. 3.458.622. teaches that tablets for controlling the release of medicinal agents for up to 8 hours can be formed from a blend ofa polymeric vinyl pyrrolidone with a carboxy vinyl hydrophilic polymer; Weil et al.. U.S. Pat. No. 3.469.005. teach that drugs for reducing blood pressure in mammals can be incorporated into solid vehicles such as lactose. cornstarch. microcrystalline cellulose. talc. stearic acid. magnesium stearate. gums. etc.; Merabi et al.. U.S. Pat. No. 3.495.000. have found that controlled release matrices can be prepared consisting of a dialdehyde starch and ethyl cellulose. polyvinyl chloride or polyvinylpyrrolidone. but that mixtures of the same starches with other pharmaceutically acceptable polymers such as methylcellulose or carboxymethylcellulose do not yield compositions suitable for controlled release: and Herrmann. U.S. Pat. No. 2155.658. teaches that medical preparations for injection into the body which are flowable above body temperature but solid at body temperature after injection can be made from polymer ized vinyl alcohols and their water soluble derivatives and a solvent for such material.

Another technique for incorporating drugs into polymeric matrices is described in Levesque. US. Pat. No. 2.987.445 and in Endicott. US. Pat. No. 3.087.860. These patents teach a drug dispenser formed from synthetic polymers containing solid particles of a waterleachable drug. Usually the polymer matrix is shaped in the form of a pill which is intended to be orally in gested. This drug dispenser is limited. however. to watersoluble drugs and has relatively short release times. i.e.. typically 8-12 hours.

While the above-mentioned patents describe various mixtures of drugs with polymers. Long et al. have taught another method for constructing a controlled release device from polymers in U.S. Pat. No. 3.279.996. Long et al. form a capsule or container from polysiloxane which is intended for implantation. This device has the advantage of making extended timerelease treatment possible. but suffers a disadvantage since the possibility exists that the polysiloxane container will develop pinholes or a rupture resulting in an undesired and potentially harmful large amount of drug being released almost instantaneously.

A polymeric drug dispenser formed from crystalline polymeric materials is disclosed in my copending application Ser. No. l02.432 filed concurrently herewith. The device described therein offers many improvements over existing controlled release devices. but suffers a disadvantage when subcutaneously implanted since the polymers described therein are not biodegradable. Thus. a separate removal step often necessitating minor surgery is required. This invention overcomes that problem.

SUMMARY OF THE INVENTION A drug dispersed in a biodegradable polymeric material can be formed to a solid shape which will unexpectedly exude the drug to the surface of the polymeric article. For purposes of this description. the term exude is used to mean the migration from the interior of the polymeric material to its surface until the surface is covered with a layer of the drug and an equilibrium is established between the surface layer and the drug at the interior of the polymeric material. lf the surface layer is partially or totally removed. the equilibrium is destroyed and further amounts of the drug permeate to the surface until equilibrium is re-established. This cycle will repeat itself until the supply of drug has been exhausted from the polymeric material. The surface layer can be removed in many ways. including but not limited to: rubbing it off; brushing it off; washing it off; dissolving it off; etc.

Relying upon this discovery. a novel article for dispensing drugs has been invented which comprises:

1. a biodegradable polymeric material formed to a solid shaped article; and.

3 2. a drug substantially uniformly and intimately dispersed throughout portions of the polymeric article.

This drug dispenser has the same advantages over prior art dispensers as the dispenser described in my above-mentioned copending application. For example. this drug dispenser provides an economical and reliable method for automatically dispensing controlled quantities of a drug over a short or an extended period of time. Such a device can be implanted within a mammals body so that it will dispense the required amounts of one or more drugs continuously over extended periods of time without the patient having to rely on periodic injections or oral ingestion of drugs. Once implanted. the dispenser can be forgotten and the patient can rest assured that his body is continuously and automatically receiving the prescribed amount of drug.

A particularly unique advantage of this device is found in the types of therapy where it is desirable to m sure that a patient receives a certain amount of a drug. and it is desirable to place control of administering the drug beyond the patient. This obviates the possibility that the patient will forget to administer the drug. It also prevents the patient from deliberately not administering the drug on his own volition. which has heretofore been a serious problem in many types of medical treatment. Once implanted. the drug dispensing devices of this invention are effectively out of the control of the patient.

A most important advantage of the polymeric drug dispenser described herein is the degree of flexibility which can be obtained in administration techniques. As stated above. one suitable method for releasing the drug from this device to a mammals bloodstream is to subcutaneously implant the device. There are many other methods. however. For example. the device can be extruded into the shape of thin spaghetti which can be injected into the bloodstream, or the polymeric material can be formed into various sized spheroids for ingestion or injection by a patient. Additionally, the polymeric material can be formed into hollow tubing suitable for catheters. In short. the dispenser of this invention can be formed into limitless solid shapes each suitable for particular methods of controllably releasing a drug to the patients bloodstream.

As mentioned above. the drug dispenser described herein has the additional advantage of a biodegradable polymeric matrix. It should be clear that this is particularly important when the device is subcutaneously implanted.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. I is a graphical representation of the controlled release of the drug Cyclazocine from three devices of this invention to the bloodstream of rats.

FIGS. 11 (GI-it) are perspective views of some of the variety of shapes of contro11ed-release, biodegradable drug dispensers of this invention;

FIG. III is a perspective view showing the subcutaneous implantation of a controlled release film device of this invention into the back of a rat.

DESCRIPTION OF THE PREFERRED EMBODIMENTS The polymeric materials used to manufacture the instant device must have high melting points so that they wont soften when exposed to fairly high temperatures such as those encountered with human body fluids. Preferably the material will have a melting point of 100C. or more so that the device can be sterilized at high temperatures.

A further limitation on suitable polymeric materials is that they be biodegradable. The term biodegradable" is used to mean materials which are attacked and broken down into simpler chemical species by substances found in mammals such as enzymes.

Some naturally occurring polymers such as sugar phosphates are known to be biodegradable.

Synthetic polymers can also be prepared which are biodegradable. Examples include polylactides and polyglycolic acid. These are the preferred biodegrad able polymers for use in this invention because they are broken down into innocuous products like carbon dioxide and water and because they are commercially available.

Useful polylactides include both homopolymers and copolymers. Usually. these polylactides are prepared from the cyclic esters of lactic acids. Both Lt+1 and D() forms of lactic acid may be used to prepare the polylactides as well as the optically inactive DL-lactic acid mixture or any desired mixtures ofD() and 1.1+) lactic acids.

Lactide copolymers offer an important degree of flexibility in choosing the life ofa polymer matrix since this can be controlled through the amount and type of comonomer used. Some illustrative examples of suitable comonomers include: glycolide. fipropiolactone. tetramethylglycolide. fibutylrolactone. tetramethylglycolide. B-butyrolactone. gamma-butyrolactone. pivalolactone. and intermolecular cyclic esters of a-hydroxybutyric acid. a-hydroxyisobutyric acid. a-hydroxyvaleric acid. a-hydroxyisovaleric acid. a-hydroxycaproic acid. a-hydroxy-a-ethylbutyric acid. oi-hydroxyisocaproic acid. a-hydroxy-B-methylvaleric acid. a-hydroxyheptanoic acid. a-hydroxyoctanoic acid. oz-bydroxydecanoic acid, a-hydroxymyristic acid. or-hydroxystearic acid. whydroxylignocenic acid. and B-phenyllactic acid.

Methods of preparing polylactides are well documented in the patent literature. The following US. Pat. Nos. the teachings of which are hereby incorporated by reference. describe in detail suitable polylactides. their properties and their preparation: Dorough. 1.995.971); Schneider. 2.703.316. Salzberg. 2.758.987. Zeile. 2.951.828; Higgins. 2.676.945; 2.683.136. Trehu. 3.531.561; British Patent specification Nos. 755.447: 779.291. 825.335. 901.037; 932.382. 1.048.088. 1.123.445: West German Pat. Nos. 946.664. 975.191. 1.112.293. 1.152.258; 1.153.902: East German Pat. Nos. 14.548; French Pat. Nos. 1.425.333; 1.478.694. 1.512.182; Netherlands Pat. No. 99.836; Netherlands Patent application Nos. 6.605.197. 6.605.292; Japanese Nos. 17.675 (19661; 7.796 (1967). 2.948 (1968): 15.78911969].

Polyglycolic acids have recently been found to possess excellent biodegradable properties. Polyglycolic acid is the homopolymer of glycolic acid (hydroxya cetic acid). In the conversion of glycolic acid to poly glycolic acid. glycolic acid is initially reacted with itself to form the cyclic ester glycolide. which in the presence of heat and a catalyst is converted to a high molecular weight linear-chain polymer. Polyglycolic acids and their properties are described in more detail in the following article. the teachings of which are hereby incorporated by reference: Cyan-amid Research Develops Worlds First Synthetic Absorbable Suture"; (lwinivn'y and Industry. July 1 l. 1970. page 905.

The molecular weights of polypeptides and polyglycolic acid are closely related to both the exudation of the drug and the biodegradation of the matrix. lt has been found that high molecular weights. i.e.. Mw=9().000 or higher result in polymer matrices which retain their structural integrity for longer periods of time; while lower molecular weights. i.e.. lviw=3U.0OU or below. result in both slower exudation and shorter matrix lives.

Crystallinity also affects the exudation and biodegradability rates. The polymer matrices having higher degrees of crystallinity have slower exudation rates and slower biodegradability. lt is known. of course. that crystallinity has a marked effect on physical properties. See Flory. Paul 1.. Principles uj'Po/ymer Chemistry. 5th printing. 1966 at pages 49 et seq. it has also been reported in the literature that gaseous diffusion through polymeric membranes is slower. in general. for those polymers having higher degrees of crystallinity than for those with lower degrees of crystallinity. See Michaels. A. S. and Bixler. H. 1.. Flow of Gases through Polyethylene and Rubbery Polymers. J. Poly. Sci. vol. 50. pages 413-439 (196i).

A good amount of control over the release of drug can be obtained by choosing appropriate molecular weights and degrees of crystallinity in the polymer matrix. For example. if a relatively long release duration is desired. a high molecular weight polymer formed from a pure optical isomer oflactic acid can be used for the matrix; on the other hand. if a rapid release rate is desirable over a short duration. a low molecular weight lactide copolymer having a lower degree of crystallinity can be synthesized for use as the polymer matrix. Those skilled in the art will know or be able to determine by routine experimentation many suitable combinations of molecular weights and degrees of crystallinities of polylactides or polyglycolic acid to accomplish a desired release rate and duration.

Surprisingly. it has also been found that the drug release rate can be controlled at the time the polymer matrix is formed into a shaped article. This can be seen from the data presented in Example I. The release rate for poly(L-)lactide films is faster for films pressed at lower temperatures than for films pressed at higher temperatures.

Using one or more of the above parameters. polymeric matrices can be designed which have a great variety of exudation rates and biodegradability. Matrices can be synthesized to have lives shorter than. equal to or longer than the period of effective drug delivery. For the shorter matrix lives. drug delivery will be accomplished by a combination of drug exudation and matrix biodegradation: for the longer matrix lives. drug delivery will be substantially dependent on only drug exudation. The degree of flexibility thus offered in designing drug dispensing systems of this invention is of great significance.

The biodegradable polymeric materials described above have drugs incorporated in them to form the article of this invention. The term drug is used in this description in its broadest sense and covers drugs useful to any mammals including. but not limited to. human beings. wild animals. household animals. and animals raised for their meat or other products such as farm animals and cattle. The term drug is further used in describing this invention to include. but not limited to. the following classes of drugs: (1) therapeutic drugs; (2) preventative drugs; and. (3) diagnostic drugs. It should be understood that a variety of classes. subclasses. and specific examples of drugs not expressly mentioned herein are within the scope of this invention. and these other drugs will be well known or easily ascertainable to those skilled in the art.

Some specific examples of drugs which can be incorporated in crystalline polymers to form a device of this invention are described infra.

As is well known. people suffering from sugar diabetes are required to take daily doses of diabetes control agents. insulin or the active ingredients in some of the commercially available control agents such as tolbuta mide (Orin-Lise" by Upjohn). chloropropamide (Di abinese" by Pfizer) and tolazamide (Tolinase" by Upjohn] could be dispensed with an article of this invention.

Many drugs are presently being used to treat rheuma toid arthritis and other forms of arthritis. These include. but are not limited to. narcotic pain relievers. gold salts. corticosteroids. adrenocorticotropic hormones. phenylbutazone and its derivatives. antimalarials. and indole derivatives. A comprehensive listing of specific drugs used to treat the various forms of arthritis is given in the Aug. 12. l968 edition of Chemical and Engineering News at pages 54 and 55. which listing is herein incorporated by reference. These drugs could be dispensed with the instant article.

Antibiotics are a further group of drugs which can be dispensed. Some examples of suitable antiobiotics include the tetracyclines. penicillan. streptomycin. and aureomycin.

Deworming and distemper drugs such as those given to household pets and/or cattle are another group of drugs capable of being dispensed by the device of this invention. An example of such a drug is phenothiazine.

Sulfur drugs such as sulfisoxazole diolamine (Gantrisin" by Roche Laboratory). useful in treating urinary tract infections. could also be exuded from a crystalline polymeric article.

Another group of drugs suitable for use in the crystalline polymeric articles are the cancer-control agents. An example would be the drugs or combinations of drugs useful for treating leukemia such as the nitrogen mustard p (di2-chlorethyl) amino-phenylbutyric acid.

Two further groups of drugs which could be advantageously dispensed with the hereindescribed device are alcohol-addiction control agents and tobacco-smoking addiction control agents.

Closely related are the addictive drug antagonists. If an addictive drug such as heroin. morphine. codeine. neopine. etc. is taken while the blood still contains the antagonist. the addictive drug will pass through the body and be harmless to the taker in the sense that the taker will not experience a high" and the drug will not be addictive. Such antagonists have offered a very successful method for treating drug addicts while the addicts are at clinics; however. it has been noted that once an addict returns to his original environment. and is out of control of the clinic. he is likely to stop taking the antagonist and resume taking one of the addictive drugs. For this reason. the article of this invention offers unique advantages in treating drug addicts by this method since such an article containing an antagonist could be implanted within the addict's body, thereby giving him no control over the administering of the antagonist. This will extend the addicts period ofcure beyond the time that he can actually be confined to a clinic. Some examples of specific drug antagonists suit able for incorporation into the polymeric dispenser include l\lallylnoroxymorphone (N-aloxone and 2- cyclopropylmethyli hydroxy-5, 9-dimethyl-(1,7- benzomorphone (Cyclazocinej. Other drug control agents such as "Mctltadone can also be used.

Two further groups of closely related drugs are the thyroid gland regulating drugs and weight-control drugs. Here again, there is a particular advantage to the use of the polymeric dispenser since such a device can be implanted within the body of the patient and thereby supply the required amount of drug without the patient having any control over this. Also, it is known that these types of drugs are extremely dangerous when taken in large doses, and the use of this device would help assure that an overdose did not get into the patients bloodstream.

Another group of drugs which could be dispensed are the analgesic drugs. These drugs have little or no therapeutic effect, but serve to lessen or eliminate the severe pain often encountered with many diseases or operations. For example, in the cases of chest cancer, morphine or codeine are often prescribed. Also, for patients suffering from cancer ofthe prostate glands, progesterone is often prescribed. One particularly advantageous use of the polymeric dispenser would be in serious surgical operations which result in severe pain to the patient after the operation is completed and the patient regains consciousness. In these cases, the body is going to be opened for the operation, and a device of this invention containing a pain killer could be inserted into the body during the operation to ease the pain to the patient during the recovery period. Of course, there are many other types of analgesic drugs and many other examples of when such drugs could be used which will be apparent to those knowledgeable in the field of medicine.

Another group of drugs suitable for being dispensed from the polymeric article are the hormone-regulating drugs to aid fertilization or to act as contraceptives. One preferred embodiment using hormone'regulating drugs is formed using the active ingredients in oral contraceptives. The advantage is that a device containing the active ingredients of oral contraceptives could be designed to last over extended periods of time thereby relieving the taker from a daily routine of orally taking the contraceptives. Suitable examples of the active in gredients in oral contraceptives include a progestin or a combination of a progestin and an estrogen. For example, a homogeneous dispersion of the active ingredient in Norethindrone" and Mestranol in a ratio of by weight could be prepared and incorporated into the solid polymeric material. Other examples of synthetic progesterones and estrogens suitable for use with this invention include: Norethynodrel, Medroxyprogesterone acetate, Dimethisterone, Ethynodiol diacetate, and Chlormadinone acetate, Norethindrone acetate and Ethynylestradiol.

Other drugs which can be incorporated in the sys tems of this invention include: drugs for reducing blood pressure such as those described in U.S. Pat. NO. 3,469,005; pharmaceutical compositions for the control of appetite such as the combinations of ampheta mines and thioridazines described in U.S. Pat. No. 3,495,005; and. agents for treating psychosis in mammals such as those described in U.S. Pat. No. 3,495,007.

The above listing of drugs is not intended to be comprehensive, but merely representative of the wide variety of drugs which can be used with this invention. Those skilled in the art will know or be able to determine by routine experimentation that many other specific drugs are also suitable.

The amount of drug dispersed in the polymeric article will depend, of course, on many factors including the specific drug, the function to be accomplished, the length of time it is desired to dispense the drug, the amount of drug to be dispensed in a specified time, the size of the device, and many other factors. In general, amounts ranging from about 0.5 percent to about percent by weight of the polymeric material can be incorporated. Particularly good results can be obtained with from at least about 10 percent to about 20 percent,

The amount of drug to be dispensed in a specified time, will of course, depend on such factors as the particular application, the particular drug, the age of the patient, etc, In general, what will constitute an effective amount" will be known or easily ascertainable by those skilled in the art. Much of this type of data is published in the literature or easily determined by routine experimentation. Examples of the published literature on effective amounts of progestin-type steroids, in this case for topical application, can be found at: Shipley, Effectiveness of Topical Application of a Number of Progestins, Steroids 5(5): 699-7l7, May 1965-, and Ringler, Efficacy of Topically Applied Progestational Agents, Steroids 7 (4): 34l349, April, 1966.111 a like manner, the following literature describes effective amounts of addictive drug antagonists: Martin. W. R., "Opioid Antagonists,- Pharmacological Reviews, vol. 19, no. 4, pages 463-52] (1967) and references contained therein; Freedman, A. M., Cyclazocine and Methadone in Narcotic Addiction, The Journal of the American Medical Association, October 16, 1967, vol. 202, pages l9]]94. Also, the patents mentioned above often contain data on effective amounts for any particular application.

In addition to the control over delivery of drug which can be obtained through proper choice and design of the polymer matrix as discussed supra, the dosage administered by this dispenser can be controlled by the size and shape of the article, concentration of the drug in the polymer, surface area, pore size, matching of the polymer and drug, nature of the surroundings, etc. This is a particular advantage where it is desirable to deliver a metered amount of the drug over a specified period of time.

Of course, combinations of drugs and substances in addition to drugs can also be incorporated into the polymeric material. For example. radioactive tracers such as carbon-l4, nonradioactive tracers such as barium sulfate, carriers which would transport the drug through skin such as dimethylsulfoxide and dimethylsulfone, water-soluble excipients. etc. could be incorporated with certain drugs for particular applications. The amount of auxiliary agent used will depend, of course, on the specific agent, drug and polymer used to fabricate the article as well as the purpose for incorporating the auxiliary agent.

As has been described. the polymeric article dispenses the drug it contains by exuding it to the surface of the article. The mechanism of how the drug enters the body from the polymer surface is not critical and can be accomplished with a variety of techniques. For example, the article may be placed upon a persons body in contact with the skin so that the particular drug could be absorbed through the persons skin into the bloodstream. An alternative technique is to implant the device within the patients body at a location where the surface layer of drug will be in contact with any of the various body fluids or tissue so that the drug could be dissolved and/or carried away by such body fluids or rubbed off and absorbed by the tissue. Subcutaneous implantation ofa film drug dispenser under the skin on the back of a rat is shown in FIG. III; a more detailed description of such implantation techniques is presented in the Example. Intramuscular implantation is also contemplated. Still another technique would be to prepare the article for use in the patients mouth so that the saliva would carry the drug into the body. In certain cases. it might be advantageous to insert the dispenser in other body cavities such as the uterus. Other techniques for getting the material from the surface of the article into the body will be readily apparent to the medical profession.

The dispensing articles described herein can be formed by pre-mixing the polymer. drug and any auxiliary agents to be incorporated with the drug and then following conventional techniques to shape and set the article. For example. the polymer and drug can be mixed together in a suitable solvent until a homogeneous solution is formed. After driving off solvent. the residue can be molded. extruded, etc. to the desired shape. Another method of forming the dispenser might be to compact at elevated pressures a dry mixture of drug and polymer. Also. monomer and drug can be mixed with subsequent polymerization of the monomer.

Another method of forming the drug dispensers is to soak a previously shaped piece of polymeric material in a solution of the drug to be incorporated. and subsequently drying the surface of the article. This technique must be distinguished, however. from simply dipping a polymeric article in a solution to coat the surface of the article with a substance. In the soaking technique of this invention. the conditions. i.e.. solvent. polymer. temperature. etc.. must be carefully chosen to insure that the active ingredient penetrates deeply into the polymer matrix instead of remaining only on the surface or penetrating a small distance below the surface as a coating does. One way to accomplish the desired deep penetration is to choose a solvent which causes the polymer to swell in the solution of drug. Some solvents cause swelling at room temperatures; others require elevated temperatures. Once the polymer has swollen. solvent and active ingredient can penetrate deeply into the polymer matrix. With rapid cooling. the polymer returns its non-swollen condition trapping solvent and active ingredient within it. If the solvent chosen is highly volatile. while the active ingredient is not. the solvent can be driven out of the article by continuous pumping. i.e.. exposing the article to reduced pressures. Those skilled in the art will be able to select appropriate conditions for carrying out this technique.

Other methods for making the polymeric dispensing articles will be apparent to those skilled in the art.

An important feature of the dispenser. which results from the way it is prepared. is that there is a substantially intimate and uniform dispersion of drug throughout the polymer. This is to be contrasted with a foraminous plastic matrix containing discrete solid particles of a drug only within the voids. such as described in U.S. Pat. Nos. 2.987.445 and 3.087.860. In these patented systems. drug release is predicated upon water or other liquids leaching the drug from the voids; in the dispenser of this invention. drug release is predicated upon exudation of the drug to the polymer surface.

Another important feature of the dispenser. which also results from the way it is prepared, is that the dis penser can be made to have structural integrity. This means that the shaped dispenser will remain intact after prolonged exposure to body fluids. Although it is difficult to list all of the factors which contribute to the structural integrity. some include: substantial nonsolubility and non-swellability in water or body fluids; relatively high tensile strengths; and good elongation at break and tensile modulus. Additionally, the polymeric matrices of this invention do not soften appreciably at temperatures as high as C. as many of the prior art waxy binders do.

A test to establish structural integrity is as follows. The shaped drug carrier is immersed in distilled water at 37C. for 7 days. After this period. weight loss of carrier and dimensional changes of carrier should be less than 10 percent of their original values. The polymeric matrices of this invention meet this test.

The shape of the dispenser will depend on its intended use. Any shape is within the scope of this invention. Some possible and preferred shapes are illustrated in FIG. 11 wherein (a) illustrates a film. (b) illustrates a piece of hollow tubing. and (c) illustrates various sized solid spheroids which could be injected into a patient or orally ingested by the patient. Other shapes contemplated but not shown include solid sphagettilike" and fiber-like" configurations and a mesh configuration which would be expected to minimize the possibility of a device subcutaneously implanted causing blood clotting. Another embodiment comprises a sphere formed from an outer coating of polylactide with a solution of drug at the center.

As is evident from the forgoing discussion. the article of this invention has many uses. all of which fall within the general utility of dispensing drugs to mammals.

The following Example serves to further illustrate the invention. All parts and percentages are by weight. unless otherwise specified.

EXAMPLE I IMPLANT PREPARED FROM A POLYLACTIDE FILM CONTAINING CYCLAZOCINE Six grams of polylactide with a molecular weight of about 40.000 prepared from L(-) lactide according to Example I of British Patent specification 1.040.168 is dissolved in 250 milliliters of chloroform. Three grams of tributylcitrate and 2.25 grams of cyclazocine are added to the hot stirred solution. This is followed by the addition of five milliliters of a trace of radioactive cyclazocine to monitor drug release. The solution is evaporated to about one-halfits original volume and poured onto glass plates. The residue on the plate is air-dried for 20 minutes and oven-baked at 100C. for 9% hour. Films are prepared by pressing the dried material between sheets of aluminum foil on a Carver press at 140C, 135C. and 130C. all at 10,000 p.s.i.

Pieces of a film prepared as above were cut into two centimeter square areas. Some pieces were weighed.

b. an effective amount of a solution of a drug said solution of drug substantially at the center of said spheroids exuding or migrating. upon implantation. from the interior to the surface of the spheroid combusted and radioassayed to provide a measure of Until 531d surface is Coated with 11 g 811d an q the concentration of radioactivity present in each li ri miS fi lfl li hed betw en the surface layer and piece. Other pieces of the same film were implanted the drug at the interior of the polymeric material subcutaneously in the backs of rats under light ether such that if the surface layer is partially or totally anesthesia. The stab wounds were sutured and rcremoved the equilibrium is destroyed and further mained so until the end ofthe experiment at which time amounts of the drug migrate to the surface until the wounds were reopened and remaining implants equilibrium is reestablished so that this cycle rewere removed for final radioassay. Little remained of peats itself until the supply of drug is exhausted. initial implant, after 62 daysv 2. An article according to claim 1 wherein said drug The rats were placed in Acme metabolism cages for comprises a contraceptive steroid present in an effec- 62 days for the separation and collection of urine and tive contraceptive amount. samples. Total daily urinary radioactivity was measured 3. An article according to claim 2 wherein said condaily for the first ten days and every four days thereaftraceptive steroid comprises a progestin. Th5 was aCCOmpllshed y liquid Scimillmlon tech- 4. An article according to claim 2 wherein said conniques and the data was repo 85 P Of (1088 traceptive steroid comprises a combination ofa proges' excreted per day" and also as cumulative percent of i d an eslmgen C1056" The final radloassal indicated that of the 5. A method for administering predetermined, effecclazocine was released from each device in each rat. i amounts f a d f an i l m a mamma] The results are presented in Table l. which comprises implanting the article of claim I in a TABLE I CYCLAZOC'INE RELEASED, CUMULATIVE Film Pressed at 140T.

Day: 1 2 3 4 5 6 7 8 9 10 ll l2 l3 I4 15 16 17 1B 19 20 Rat: A 6.9 11.9 14.9 16.1 17.0 18.0 18.7 19.4 20.0 20.7 21.0 21.3 21.6 21.9 22.2 22.5 22.8 23. 23.4 23. B 4.4 7.7 9.2 10.5 11.6 12.3 13.5 14.3 15.4 16.7 17.3 17.9 18.5 19.1 19,3 19.5 19.7 19.9 20.1 20. C 0.8 4.1 6.1 7.5 9.3 10.5 11.3 12.3 13314.1 14.6 15.1 15.6 16.1 16.6 17.1 17.6 18.1 18.3 18.

Film Pressed at 135C.

Day: 1 2 3 4 S 6 7 8 9 10 Rat: D 38.0 63.6 76.9 78.4 80.8 81.5 81.8 82.2 82.4 82.5 E 17.0 32.0 39.3 45.1 50.0 53.6 56.8 60.2 63.4 65.9 F 14.0 24.3 25.3 28.2 32.1 34.6 37.7 40.1 41.5 425 Film Pressed at 130C.

Day: 1 2 3 4 5 6 7 8 9 10 Rat. CI 30.7 62.4 81.9 89.0 895 89.8 90.0 90.2 90.5 91.7 H 15.2 37.0 58.6 75.5 83.8 84.6 84.8 84.9 851 85.8

RAT AND IMPLANT DATA Initial Initial Implant Initial Weight gm. Weight. gm. DPM Rat A 645 0.0671 1870000 B 520 0.0708 2,080,000 C 350 0.0732 2.150000 D 690 0.0512 1.475000 E 670 0.0548 1.580000 F 5 0.0690 1.990.000 G 520 0.0791 2.070.000 H 580 0.0942 2,450.000

What is claimed is:

I. An article for controllably dispensing drugs comprising:

a. a plurality of spheroidal shaped. homopolymers and copolymers of lactic acid, said polymers being prepared from cyclic esters of optically active or inactive lactic acids. or mixtures thereof. having a sufticiently high molecular weight to retain structural integrity of said spheroids for an effective period of time upon implantation. with the proviso that crystalline spheroids having relatively long du ration upon implantation are formed from pure op tic-ally active lactic acids and spheroids having rapid release upon implantation are formed from lactic acid polymers having a lower degree of crys tallinity with

Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US2625158 *14 juin 195013 janv. 1953Alexander William MSubcutaneous medication
US3297033 *31 oct. 196310 janv. 1967American Cyanamid CoSurgical sutures
US3435008 *22 août 196725 mars 1969American Cyanamid CoMethod for preparation of isomerically pure beta-glycolide and polymerization method for glycolide compositions employing partial hydrolyzate of said beta-glycolide
US3499445 *16 août 196610 mars 1970Phytogen Prod IncAnimal husbandry
US3545439 *4 janv. 19688 déc. 1970Upjohn CoMedicated devices and methods
US3565991 *22 avr. 196823 févr. 1971Searle & CoMethods for use and compositions of 17alpha-ethyl-19-nortestosterone and carriers for the sustained release of steroids
US3618213 *27 avr. 19709 nov. 1971Nat Patent Dev CorpDenture liners
US3625214 *18 mai 19707 déc. 1971Alza CorpDrug-delivery device
US3636956 *13 mai 197025 janv. 1972Ethicon IncPolylactide sutures
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US3976071 *7 janv. 197424 août 1976Dynatech CorporationMethods of improving control of release rates and products useful in same
US3991766 *3 avr. 197516 nov. 1976American Cyanamid CompanyControlled release of medicaments using polymers from glycolic acid
US4001388 *2 juil. 19754 janv. 1977Alza CorporationPolyesters
US4011312 *25 juin 19758 mars 1977American Home Products CorporationProlonged release drug form for the treatment of bovine mastitis
US4066747 *8 avr. 19763 janv. 1978Alza CorporationPolymeric orthoesters housing beneficial drug for controlled release therefrom
US4093709 *28 janv. 19756 juin 1978Alza CorporationDrug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4115544 *10 nov. 197719 sept. 1978Alza CorporationOcular system made of bioerodible esters having linear ether
US4138344 *24 août 19776 févr. 1979Alza CorporationErodible agent releasing device comprising poly(orthoesters) and poly(orthocarbonates)
US4148871 *11 oct. 197710 avr. 1979Pitt Colin GSustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers
US4239755 *28 juin 197916 déc. 1980The United States Of America As Represented By The Department Of Health, Education And WelfareSteroidal cyclotriphosphazenes
US4272398 *15 juin 19799 juin 1981The United States Of America As Represented By The Secretary Of AgricultureMicroencapsulation process
US4273920 *12 sept. 197916 juin 1981Eli Lilly And CompanyCopolymer of lactic and glycolit acids using acid ion exchange resin catalyst
US4291013 *9 oct. 197922 sept. 1981Merck Patent Gesellschaft Mit Beschrankter HaftungMedicinally useful, shaped mass of collagen resorbable in the body
US4293539 *12 sept. 19796 oct. 1981Eli Lilly And CompanyControlled release formulations and method of treatment
US4322398 *21 févr. 197930 mars 1982Battelle Institut E.V.Implantable drug depot and process for the production thereof
US4326522 *9 juin 198027 avr. 1982Pitman-Moore, Inc.Mesh-covered bolus
US4331652 *24 déc. 198025 mai 1982Eli Lilly And CompanyControlled release parasitic formulations and method
US4333919 *15 déc. 19808 juin 1982Eli Lilly And CompanyGrowth promotant controlled release formulations and method of treatment
US4347234 *15 juin 198131 août 1982Merck Patent Gesellschaft Mit Beschrankter HaftungMedicinally useful, shaped mass of collagen resorbable in the body
US4351337 *11 sept. 198028 sept. 1982Arthur D. Little, Inc.Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4419340 *20 nov. 19806 déc. 1983University Of DelawareControlled release of anticancer agents from biodegradable polymers
US4491575 *6 oct. 19831 janv. 1985Chemie Linz AktiengesellschaftCompressed products with retarded release of active substance, a process for their preparation and a process for the long-term administration of medicaments
US4526938 *15 avr. 19832 juil. 1985Imperial Chemical Industries PlcContinuous release formulations
US4578384 *15 févr. 198425 mars 1986The United States Of America As Represented By The Secretary Of The ArmyPolylactic-polyglycolic acids combined with an acidic phospholipid-lysozyme complex for healing osseous tissue
US4585651 *18 déc. 198029 avr. 1986Stolle Research & Development CorporationAntifertility vaccine
US4622244 *23 août 198411 nov. 1986The Washington UniversityProcess for preparation of microcapsules
US4649042 *3 avr. 198510 mars 1987Eli Lilly And CompanyRumen delivery device
US4666702 *11 avr. 198519 mai 1987Thiemann Arzneimittel GmbhDosage units for controlled release of active material
US4675189 *8 févr. 198523 juin 1987Syntex (U.S.A.) Inc.Microencapsulation of water soluble active polypeptides
US4685883 *26 juil. 198511 août 1987Jernberg Gary RBiodegradable microsperes inserted in gums
US4702917 *18 nov. 198527 oct. 1987Research Triangle InstituteShaping blend of polylactones and polyethers then leaching out the polyether
US4707362 *15 févr. 198517 nov. 1987Biotek, Inc.Sustained release composition
US4732763 *28 sept. 198422 mars 1988Stolle Research And Development CorporationActive/passive immunization of the internal female reproductive organs
US4745160 *21 juin 198517 mai 1988Imperial Chemical Industries PlcBiodegradable amphipathic copolymers
US4754745 *7 juil. 19865 juil. 1988Horowitz Bruce SConformable sheet material for use in brachytherapy
US4763642 *7 avr. 198616 août 1988Horowitz Bruce SIntracavitational brachytherapy
US4767628 *29 juin 198730 août 1988Imperial Chemical Industries PlcPolylactone and acid stable polypeptide
US4774091 *31 mars 198627 sept. 1988Sumitomo Pharmaceuticals Company, Ltd.Protein carriers
US4806621 *21 janv. 198621 févr. 1989Massachusetts Institute Of TechnologyBiocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US4815449 *30 mars 198728 mars 1989Horowitz Bruce SDelivery system for interstitial radiation therapy including substantially non-deflecting elongated member
US4832686 *24 juin 198623 mai 1989Anderson Mark EMethod for administering interleukin-2
US4835139 *19 mai 198730 mai 1989Debiopharm S.A.Process for increasing the antagonistic effect of peptidic compounds on hormone-dependent diseases
US4841968 *26 sept. 198627 juin 1989Southern Research InstituteAntithrombotic/thrombolytic suture and methods of making and using the same
US4857049 *5 août 198615 août 1989Kortum, Inc.Method and apparatus for inducing immunological and resistant response in mammary glands
US4871542 *30 avr. 19873 oct. 1989Ferring Service Center, N.V.Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract
US4877606 *19 janv. 198831 oct. 1989Imperial Chemical Industries PlcFreeze dried, stable aqueous dispersion of drug
US4897268 *3 août 198730 janv. 1990Southern Research InstituteDrug delivery system and method of making the same
US4898734 *29 févr. 19886 févr. 1990Massachusetts Institute Of TechnologyTransdermal drug delivery, vascular grafts, wound-healing films or polymbric porous membrane
US4938763 *3 oct. 19883 juil. 1990Dunn Richard LBiodegradable in-situ forming implants and methods of producing the same
US4940588 *17 mars 198810 juil. 1990Elan CorporationControlled release powder and process for its preparation
US4961707 *6 juin 19899 oct. 1990University Of FloridaGuided periodontal tissue regeneration
US5004602 *12 mai 19862 avr. 1991Imperial Chemical Industries PlcContinuous release pharmaceutical compositions formed by freeze drying acetic acid solutions of polylactide
US5021241 *28 avr. 19884 juin 1991Sumitomo Pharmaceuticals Company, LimitedLong-term sustained-release preparation
US5110595 *19 juin 19875 mai 1992Wang Paul YImplant preparations containing bioactive macromolecule for sustained delivery
US5114719 *14 sept. 198919 mai 1992Sabel Bernhard APolymer matrix for drug delivery of biologically active molecules
US5142023 *24 janv. 199225 août 1992Cargill, IncorporatedConcentrating lactic acid solution, polymerizing, depolymerizing to form lactide, distilling, polymerizing
US5160341 *8 nov. 19903 nov. 1992Advanced Surgical Intervention, Inc.Resorbable urethral stent and apparatus for its insertion
US5208032 *26 juin 19924 mai 1993Rutgers, The State University Of New JerseyIncreasing the growth of turkeys using implant of 19-nortestosterone
US5236355 *5 oct. 199017 août 1993American Cyanamid CompanyApparatus for the treatment of periodontal disease
US5247058 *7 août 199221 sept. 1993Cargill, IncorporatedHigh molecular weight, catalyst to depolymerize the polylactic acid to form lactide which is then polymerized
US5247059 *24 août 199221 sept. 1993Cargill, IncorporatedContinuous process for the manufacture of a purified lactide from esters of lactic acid
US5258488 *7 août 19922 nov. 1993Cargill, IncorporatedContinuous process for manufacture of lactide polymers with controlled optical purity
US5274073 *24 août 199228 déc. 1993Cargill, IncorporatedContinuous process for manufacture of a purified lactide
US5278201 *24 avr. 199011 janv. 1994Atrix Laboratories, Inc.Polymers biodegradable by enzyme hydrolysis
US5286763 *30 juin 199215 févr. 1994Massachusetts Institute Of TechnologyBioerodible polymers for drug delivery in bone
US5338822 *2 oct. 199216 août 1994Cargill, IncorporatedMelt-stable lactide polymer composition and process for manufacture thereof
US5350580 *26 févr. 199327 sept. 1994Minnesota Mining And Manufacturing CompanySurgically inserted cylindrical sheet or coiled filament which expands to contact walls of middle ear
US5357035 *16 sept. 199318 oct. 1994Cargill, IncorporatedIncorporates removal of water or solvent carrier to concentrate the lactic acid feed followed by polymerization to a low molecular weight prepolymer
US5366733 *28 mai 199122 nov. 1994American Cyanamid CompanyMethod for the treatment of periodontal disease by sustained delivery of a therapeutic agent to the periodontal pocket, and composition of matter therefor
US5366734 *22 août 199122 nov. 1994Zeneca LimitedContinuous release pharmaceutical compositions
US5384333 *17 mars 199224 janv. 1995University Of MiamiTime release agents
US5403595 *13 oct. 19934 avr. 1995Dynagen, Inc.Contains physical constraint modulation system contining microparticle of lobaline in a biodegradable polymer to release effective amount of lobaline to diminish indivisuals desire for nicotine for a period of time
US5444113 *29 sept. 199322 août 1995Ecopol, LlcEnd use applications of biodegradable polymers
US5456917 *12 janv. 199410 oct. 1995Cambridge Scientific, Inc.Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
US5462990 *5 oct. 199331 oct. 1995Board Of Regents, The University Of Texas SystemBlock copolymers with a non-binding polynonionic component and a water soluble polycationic portion for tissue binding; useful in inhibiting post-surgical adhesions
US5475080 *22 mars 199312 déc. 1995Cargill, IncorporatedPaper having a melt-stable lactide polymer coating and process for manufacture thereof
US5484881 *23 août 199316 janv. 1996Cargill, Inc.Biodegradable, heat resistance
US5486362 *21 oct. 199323 janv. 1996Dynagen, Inc.Controlled, sustained release delivery system for treating drug dependency
US5487897 *28 sept. 199330 janv. 1996Atrix Laboratories, Inc.Thermoplastic polymer, in vivo coagulation, drug delivery, wound healing, tissue regeneration
US5500228 *26 nov. 199019 mars 1996American Cyanamid CompanyPhase separation-microencapsulated pharmaceuticals compositions useful for alleviating dental disease
US5518730 *3 juin 199221 mai 1996Fuisz Technologies Ltd.Biodegradable controlled release flash flow melt-spun delivery system
US5525706 *25 oct. 199411 juin 1996Cargill, IncorporatedMelt-stable lactide polymer nonwoven fabric and process for manufacture thereof
US5536503 *3 avr. 199516 juil. 1996Dynagen, Inc.Lobeline
US5536807 *23 août 199316 juil. 1996Cargill, IncorporatedMelt-stable semi-crystalline lactide polymer film and process for manufacture thereof
US5538733 *7 juil. 199423 juil. 1996Willmar Poultry Company, Inc.Poultry
US5539081 *22 mai 199523 juil. 1996Cargill, IncorporatedPolylactic acid and stabilizers
US5540937 *27 juil. 199330 juil. 1996Rhone MerieuxProcess for preparing microspheres for the prolonged release of the LHRH hormone and its analogues, microspheres and formulations obtained
US5545409 *5 avr. 199413 août 1996Massachusetts Institute Of TechnologyShaped matrix of polyanhydride or polyorthoester and a chondrogenic or osteogenic bioactive protein
US5585191 *13 sept. 199517 déc. 1996Cargill, IncorporatedMelt-stable amorphous lactide polymer film and process for manufacture thereof
US5599535 *7 juin 19954 févr. 1997Regents Of The University Of CaliforniaAdministering a non-steroidal antiinflammatory agent preventing cell lose in eye disorders
US5607686 *22 nov. 19944 mars 1997United States Surgical CorporationPolymeric composition
US5629009 *7 août 199613 mai 1997Massachusetts Institute Of TechnologyInducing chondrogenesis and osteogenesis by implanting shaped polyanhydride or polyorthoester matrix with bioactive substance, i.e., demineralized bone protein, tgf-beta, egf, fgf or pdgf
US5632727 *7 juin 199527 mai 1997Atrix Laboratories, Inc.Biodegradable film dressing and method for its formation
US5633002 *4 mai 199527 mai 1997Boehringer Ingelheim GmbhDrug delivery; polylactic acid carrier containing an acetic ester
US5656297 *3 mai 199412 août 1997Alkermes Controlled Therapeutics, IncorporatedModulated release from biocompatible polymers
US5660849 *23 août 199426 août 1997Atrix Laboratories, Inc.Kit comprising support for maintaining polymer thereon, means for compressing polymer, vials containing water coagulable thermoplastic polymer in water soluble organic solvent, aqueous medium
US5665474 *31 août 19959 sept. 1997Cargill, IncorporatedPaper having a melt-stable lactide polymer coating and process for manufacture thereof
US5674888 *7 juin 19957 oct. 1997University Of CaliforniaMethod for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5681873 *14 oct. 199328 oct. 1997Atrix Laboratories, Inc.Biodegradable polymeric composition
US5700479 *10 nov. 199423 déc. 1997Guidor AbBiodegradable sheet use in dentistry creating space around tooth roots for healing connective tissue
US5702716 *2 juin 199330 déc. 1997Atrix Laboratories, Inc.Polymeric compositions useful as controlled release implants
US5707647 *14 nov. 199613 janv. 1998Atrix Laboratories, Inc.Adjunctive polymer system for use with medical device
US5717030 *6 déc. 199610 févr. 1998Atrix Laboratories, Inc.Adjunctive polymer system for use with medical device
US5722950 *7 juin 19953 mars 1998Atrix Laboratories, Inc.Method for remote delivery of an aerosolized liquid
US5733950 *25 sept. 199531 mars 1998Atrix Laboratories, IncorporatedDissolving water insoluble biodegradable thermoplastic polymer in biocompatible water soluble solvent, placing in body, allowing solvent to dissipate or diffuse into body fluid and polymer to coagulate or solidify to form implant
US5736152 *27 oct. 19957 avr. 1998Atrix Laboratories, Inc.Mixture of biodegradable, non-polymeric, water insoluble material and a biocompatible solvent that solubilizes the non-polymeric material
US5739176 *18 mars 199414 avr. 1998Atrix Laboratories, Inc.Dissolving biocompatible water-insoluble biodegradable thermoplastic polymer in water-soluble organic solvent, placing in implant site in body, allowing solvent to diffuse or dissipate into body fluid so polymer coagulates to solid
US5741479 *6 juin 199521 avr. 1998Gillette Canada Inc.Blocking exposed tubules
US5744153 *9 juin 199728 avr. 1998Atrix Laboratories, Inc.Liquid delivery compositions
US5747060 *26 mars 19965 mai 1998Euro-Celtique, S.A.Prolonged local anesthesia with colchicine
US5756651 *17 juil. 199626 mai 1998Chronopol, Inc.Impact modified polylactide
US5760118 *5 juin 19952 juin 1998Chronopol, Inc.Paper products
US5763564 *29 mars 19969 juin 1998Cargill, IncorporatedMelt-stable lactide polymer composition and process for manufacture thereof
US5773562 *28 févr. 199630 juin 1998Cargill, IncorporatedMelt-stable semi-crystalline lactide polymer film and process for manufacture thereof
US5780044 *5 déc. 199614 juil. 1998Atrix Laboratories, Inc.Biocompatible solvent, biocompatible, biodegradable thermoplastic polymer, active material; controlled drug delivery
US5780051 *22 janv. 199714 juil. 1998Dynagen, Inc.Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
US5792469 *7 juin 199511 août 1998Atrix Laboratories, Inc.Liquid formulation of thermoplastic polymer and organic solvent
US5798436 *5 sept. 199625 août 1998Cargill, IncorporatedCatalytically polymerizing lactic acid, devolatizing polylactide produced to form solid flowable form, melting and extruding to form a film
US5807973 *27 sept. 199515 sept. 1998Cargill, IncorporatedMelt-stable lactide polymer nonwoven fabric and process for manufacture thereof
US5811128 *7 sept. 199322 sept. 1998Southern Research InstituteMethod for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5814344 *6 juin 199529 sept. 1998Southern Research InstituteMethod for delivering bioactive agents into and through the mucosally associated lymphoid tissues and controlling their release
US5820883 *6 juin 199513 oct. 1998Southern Research InstituteAdministering two separately microencapsulated active agents; first agent causes primary immune response, second agent is released in pulsating manner to potentiate response
US5852166 *14 juil. 199722 déc. 1998Cargill, IncorporatedPaper having a melt-stable lactide polymer coating and process for manufacture thereof
US5853763 *6 juin 199529 déc. 1998Southern Research InstituteMethod for delivering bioactive agents into and through the mucosally-associated lymphoid tissue and controlling their release
US5876452 *30 mai 19952 mars 1999Board Of Regents, University Of Texas SystemBiodegradable implant
US5888533 *21 nov. 199730 mars 1999Atrix Laboratories, Inc.Shorter biodegradable time, can be formed into a solid implant in situ; non-polymeric, biodegradeable water insoluble material, and a biocompatible organic solvent solubilizer
US5906617 *15 août 199725 mai 1999Meislin; Robert J.Surgical repair with hook-and-loop fastener
US5906826 *3 avr. 199625 mai 1999Willmar Poultry Company, Inc.Adminstering a biocompabilbe solid implant having the antigen releasably contained therein during a period when maternal antiboides are circulating in a mammal and are effective to stimulate active immunity
US5908918 *26 mai 19981 juin 1999Chronopol, Inc.Degradable blends containing polylactide, a degradable impact modifier, and a degradable plasticizer for use in packaging films.
US5912015 *7 avr. 199815 juin 1999Alkermes Controlled Therapeutics, Inc.Drug delivery using time-release agent having zinc or magnesium salt dispersed in matrix; biodegradable
US5916597 *29 août 199629 juin 1999Alkermes Controlled Therapeutics, Inc.Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
US5922253 *18 mai 199513 juil. 1999Alkermes Controlled Therapeutics, Inc.Production scale method of forming microparticles
US5922340 *16 sept. 199613 juil. 1999Children's Medical Center CorporationAdministering with glucocorticoid; sustained release
US5922682 *11 févr. 199213 juil. 1999Novartis AgPolyol esters, their preparation and use in depot forms of pharmacologically active agents
US5942241 *7 juin 199624 août 1999Euro-Celtique, S.A.A sustained release drug containing a substrate comprising a local anesthetic and a biocompatible, biodegradable, controlled release polymer selected from polyanhydrides, lactic acid and glycolic acid homo-or/and copolymers
US5942252 *6 juin 199524 août 1999Southern Research InstituteIncreasing the bioavailability of a drug by administering an effective amount of microcapsules to animal, the microcapsules comprising active agent encapsulated in a biocompatible and biodegradable excipient
US5945115 *8 août 199731 août 1999Atrix Laboratories, Inc.Polymeric compositions useful as controlled release implants
US5981694 *7 nov. 19979 nov. 1999Cargill, IncorporatedMelt-stable lactide polymer composition and process for manufacture thereof
US5989463 *24 sept. 199723 nov. 1999Alkermes Controlled Therapeutics, Inc.Methods for fabricating polymer-based controlled release devices
US5990194 *7 nov. 199723 nov. 1999Atrix Laboratories, Inc.Biodegradable in-situ forming implants and methods of producing the same
US6005067 *28 janv. 199821 déc. 1999Cargill IncorporatedContinuous process for manufacture of lactide polymers with controlled optical purity
US6005068 *20 juil. 199821 déc. 1999Cargill IncorporatedMelt-stable amorphous lactide polymer film and process for manufacture thereof
US6013853 *15 févr. 199411 janv. 2000The University Of Texas SystemA bioactive agent uniformly distributed in a biodegradable, at least 50%-porous polymer to supply a smooth continuous release the first two weeks of use; release profile promotes migration and differentiation of cells; bones; cartilage
US6020473 *5 déc. 19951 févr. 2000Genentech, Inc.Nucleic acids encoding variants of vascular endothelial cell growth factor
US6024983 *7 sept. 199315 févr. 2000Southern Research InstitutePotentiating immunology biocompatible excipients in microcapsules
US6046187 *16 sept. 19964 avr. 2000Children's Medical Center CorporationUse of glucocorticosteroids in methods and formulations for prolonging and/or reactivating local anesthesia or local anesthesia previously induced by a local anesthetic agent
US6057428 *2 août 19962 mai 2000Genentech, Inc.Variants of vascular endothelial cell growth factor
US6071530 *26 juin 19976 juin 2000Atrix Laboratories, Inc.Dispensing solution of biodegradable, water insoluble, thermoplastic resin with biocompatible solvent onto support; coagulation
US6071982 *18 avr. 19976 juin 2000Cambridge Scientific, Inc.Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
US6090925 *19 août 199618 juil. 2000Epic Therapeutics, Inc.Macromolecular microparticles and methods of production and use
US6093791 *9 mars 199825 juil. 2000Cargill, IncorporatedBiodegradable packaging materials, disposable products
US6109269 *30 avr. 199929 août 2000Medtronic, Inc.Method of treating addiction by brain infusion
US6111060 *2 janv. 199829 août 2000Cargill, IncorporatedComprises a plurality of poly(lactide) polymer chains, residual lactide in concentration of less than about 2 percent
US6120789 *30 mars 199919 sept. 2000Atrix Laboratories, Inc.Non-polymeric sustained release delivery system
US6121410 *27 juil. 199919 sept. 2000Cargill, IncorporatedPolylactide polymer being a reaction product of polymerizing a lactide mixture comprising less than about 15% by weight meso-lactide with the remaining lactide being selected from l-lactide, d-lactide and mixtures thereof
US6123957 *16 juil. 199726 sept. 2000Jernberg; Gary R.Combining at least one tissue regenerative agent with at least one cellular recognition agent(cra) to form a therapeutic treatment composition and applying it to a periodontal treatment site; cra increases tissue regeneration
US6126919 *7 févr. 19973 oct. 20003M Innovative Properties CompanyMetered dose inhaler for sustained release
US6143314 *28 oct. 19987 nov. 2000Atrix Laboratories, Inc.Thermoplastic resin
US6143863 *11 mai 19997 nov. 2000Cargill, IncorporatedPolylactide; residual monomer content of less than 2 wt. %; residual polymerization catalyst; and a catalyst deactivator obtained from a carboxylic acid (e.g. amide) for reducing catalytic depolymerization of the polylactide
US6153129 *5 mai 199928 nov. 2000Alkermes Controlled Therapeutics, Inc.Production scale method of forming microparticles
US617178826 sept. 19979 janv. 2001The Regents Of The University Of CaliforniaMethods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US61742994 déc. 199816 janv. 2001Harvey B. PollardMethod for treating hemophilia A and B and AIDS and devices used therein
US62035565 août 199920 mars 2001Kensey Nash CorporationTransmyocardial revascularization system and method of use
US6203813 *9 oct. 199820 mars 2001Lance L. GoobermanOpiate antagonist, steroidal antiinflammatory agent and carrier; sustained release; drug abuse treatment
US620779227 juil. 199927 mars 2001Cargill, IncorporatedMelt-stable amorphous lactide polymer film and process for manufacture thereof
US623870212 juil. 199929 mai 2001Children's Medical Center Corp.High load formulations and methods for providing prolonged local anesthesia
US62483452 juil. 199819 juin 2001Euro-Celtique, S.A.Prolonged anesthesia in joints and body spaces
US627795113 juil. 199921 août 2001Cargill, IncorporatedProviding a lactide reactor; feeding polylactic acid to lactide reactor through conduit; forming volatilized crude lactide, withinlactide reactor, upon depolymerization of polylactic acid; removing lactide
US63064257 avr. 200023 oct. 2001Southern Research InstituteTime release agents; therapy of drug abuse and drug dependence
US63264587 oct. 19934 déc. 2001Cargill, Inc.Continuous process for the manufacture of lactide and lactide polymers
US63530303 juin 19985 mars 2002Novartis AgRelating to organic compounds
US6355772 *9 mai 200012 mars 2002Cargill, IncorporatedMelt spinning polylactide composition at extrusion temperature of 150 degrees c or higher to provide fibers, drawing fibers and providing takeup velocity of 500 meters/minute
US63584436 juin 200019 mars 2002Alkermes Controlled Therapeutics, Inc.Directing microdroplets into freezing section containing a liquefied gas; contacting frozen microdroplets in extraction section with liquid non-solvent to extract solvent into non-solvent to form microparticles
US636863023 mars 19999 avr. 2002Alkermes Controlled Therapeutics, Inc.Modulated release from biocompatible polymers
US63952938 mars 200028 mai 2002Atrix LaboratoriesBiodegradable implant precursor
US64167429 août 20009 juil. 20023M Innovative Properties CompanyMedicinal aerosol solution formulation with biocompatible polymer
US64263393 avr. 200030 juil. 2002Children's Medical Center CorporationIn situ; sustained release; preadministering glucocorticosteroid
US64757247 mai 19995 nov. 2002The Regents Of The University Of CaliforniaNucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US650389430 août 20007 janv. 2003Unimed Pharmaceuticals, Inc.Pharmaceutical composition and method for treating hypogonadism
US65142711 févr. 20014 févr. 2003Kensey Nash CorporationTransmyocardial revascularization system and method of use
US651451629 juin 19994 févr. 2003Euro-Celtique, S.A.Local anesthetic and a biocompatible controlled release material consisting of polyanhydrides, copolymers of lactic acid and glycolic acid, poly(lactic) acid, poly(glycolic) acid, polyesters, polyorthoesters, proteins, polysaccharides
US651453322 sept. 19974 févr. 2003Alkermas Controlled Therapeutics, Inc.Device for the sustained release of aggregation-stabilized, biologically active agent
US652125910 mars 200018 févr. 2003Euro-Celtique S.A.Controlled release material comprising polyanhydrides, copolymers of lactic acid and glycolic acid, polylactic acid, polyglycolic acid, polyesters, polyorthoesters, proteins, polysaccharides; ouabain, digoxin
US65340812 avr. 200118 mars 2003Euro-Celtique S.A.Administration of microparticles in a form suitable for injection and containing active agents suitable for treating or diagonising a disease or painful condition in joints in a patient in need, safe and effective procedure; sustained
US654830218 juin 199915 avr. 2003Johns Hopkins University School Of MedicinePolymers for delivery of nucleic acids
US6576246 *24 mai 200010 juin 2003Seefar Technologies, Inc.Article for chewing by pets which comprises matrix comprising combination of natural and synthetic polymer materials, fibers which are dispersed throughout and bonded chemically or physically with matrix, and microbe inhibiting agents
US6579533 *30 nov. 199917 juin 2003Bioasborbable Concepts, Ltd.Bioabsorbable drug delivery system for local treatment and prevention of infections
US662760019 janv. 200130 sept. 2003Ardana Bioscience LimitedTime-release implant of drug dispersed in biodegradable polymer; shape retention; nonfused; no need for suspending fluid
US668275424 nov. 199927 janv. 2004Willmar Poultry Company, Inc.Ovo delivery of an immunogen containing implant
US669990826 sept. 20012 mars 2004Euro-Celtique, S.A.Methods for providing safe local anesthesia
US67094275 août 199923 mars 2004Kensey Nash CorporationSystems and methods for delivering agents into targeted tissue of a living being
US67268606 déc. 200127 avr. 2004Alkermes Controlled Therapeutics, Inc.Production scale method of forming microparticles
US67498663 janv. 200215 juin 2004Alkermes Controlled Therapeutics, Inc.Modulated release from biocompatible polymers
US69215419 sept. 200226 juil. 2005Euro-Celtique S.A.Formulations and methods for providing prolonged local anesthesia
US695568121 nov. 200218 oct. 2005Kensey Nash CorporationTransmyocardial revascularization system and method of use
US695815821 mars 200225 oct. 2005Ortho-Mcneil Pharmaceutical, Inc.Immune modulation device for use in animals
US697213321 avr. 20036 déc. 2005Seefar Technologies, Inc.Degradable animal chewing article possessing enhanced safety, durability and mouth-feel
US70055051 juil. 199928 févr. 2006Genentech, Inc.Variants of vascular endothelial cell growth factor
US703745023 févr. 20042 mai 2006Alkermes Controlled Therapeutics, Inc.Production scale method of forming microparticles
US706029931 déc. 200313 juin 2006Battelle Memorial InstituteBiodegradable microparticles that stabilize and control the release of proteins
US70783822 nov. 200018 juil. 2006Genentech, Inc.Modulation of eNOS activity and therapeutic uses thereof
US709441924 juin 200322 août 2006Tenhuisen Kevor Sfrom an implantable immunomodulation device having an impermeable, yet porous, biocompatible outer shell and an inner lumen of a fibrous scaffolding having an antigen or chemotatic agent sufficient to provoke an immune response
US712892714 avr. 199831 oct. 2006Qlt Usa, Inc.Emulsions for in-situ delivery systems
US713851111 janv. 199921 nov. 2006The Regents Of The University Of CaliforniaNucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US715688014 août 20032 janv. 2007Kensey Nash CorporationDevices and methods for treating defects in the tissue of a living being
US716613313 juin 200223 janv. 2007Kensey Nash CorporationDevices and methods for treating defects in the tissue of a living being
US723510714 nov. 200326 juin 2007Evans Douglas GDevices and methods for treating defects in the tissue of a living being
US724131631 juil. 200310 juil. 2007Douglas G EvansCollagen implants with improved mechanical stability and comfort for use in medicine and surgery
US741948223 janv. 20042 sept. 2008Kensey Nash CorporationSystems and methods for delivering agents into targeted tissue of a living being
US74275963 juin 200523 sept. 2008Genentech, Inc.Having mutations in the Kinase domain region (KDR) and/or the FMS-like Tyrosine-Kinase region (FLT-1), said variants exhibiting modified binding characteristics at said regions compared with native VEGF; stimulates vasculogenesis or angiogenesis; wound healing
US74762349 mars 200513 janv. 2009Kensey Nash CorporationTransmyocardial revascularization system and method of use
US759490017 avr. 200229 sept. 2009Kensey Nash CorporationSystems and methods for delivering agents into targeted tissue of a living being
US768705418 févr. 200230 mars 20103M Innovative Properties CompanySustained release; drug delivery
US788759827 oct. 200715 févr. 2011Kensey Nash Bvf Technology, LlcDevices and methods for treating defects in the tissue of a living being
US78922917 oct. 200822 févr. 2011Kensey Nash Bvf Technology, LlcDevices and methods for treating defects in the tissue of a living being
US7897168 *13 avr. 20071 mars 2011Medtronic Vascular, Inc.Degradable polymers incorporating gamma-butyrolactone
US816303222 févr. 201124 avr. 2012Kensey Nash Bvf Technology, LlcDevices and methods for treating defects in the tissue of a living being
US818764013 janv. 200929 mai 2012Dunn Research & Consulting, LlcLow viscosity liquid polymeric delivery system
US82265985 août 200324 juil. 2012Tolmar Therapeutics, Inc.Coupling syringe system and methods for obtaining a mixed composition
US826310821 juin 200211 sept. 2012Durect CorporationBiodegradable insert; drug delivery
US836703823 mai 20055 févr. 2013HMI Medical Innovations, LLCTherameutin modulators
US84016744 août 200919 mars 2013Cochlear LimitedApparatus for delivery of pharmaceuticals to the cochlea
US841980210 févr. 201116 avr. 2013Kensey Nash Bvf Technology, LlcDevices and methods for treating defects in the tissue of a living being
US842561916 nov. 201023 avr. 2013Kensey Nash Bvf Technology, LlcDevices and methods for treating defects in the tissue of a living being
US843111024 nov. 200630 avr. 2013Hmi Medical Innovations, Llc.Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
US843530616 nov. 20107 mai 2013Kensey Nash Bvf Technology LlcDevices and methods for treating defects in the tissue of a living being
US846613611 juil. 201118 juin 2013Unimed Pharmaceuticals, LlcTestosterone gel and method of use
US846613711 juil. 201118 juin 2013Unimed Pharmaceuticals, LlcTestosterone gel and method of use
US84661385 oct. 201118 juin 2013Unimed Pharmaceuticals, LlcTestosterone gel and method of use
US84869255 oct. 201116 juil. 2013Unimed Pharmaceuticals, LlcTestosterone gel and method of use
US862309410 juil. 20077 janv. 2014Kensey Nash Bvf Technology LlcDevices and methods for treating defects in the tissue of a living being
US863283922 sept. 201121 janv. 2014Covidien LpMethods of forming self-supporting films for delivery of therapeutic agents
US872905714 mars 201320 mai 2014Unimed Pharmaeuticals, LLCTestosterone gel and method of use
US874188114 mars 20133 juin 2014Unimed Pharmaceuticals, LlcTestosterone gel and method of use
US875364320 févr. 201317 juin 2014Life-Science Innovations, LlcSpray dried compositions and methods of use
US875407014 mars 201317 juin 2014Unimed Pharmaceuticals, LlcTestosterone gel and method of use
US875932914 mars 201324 juin 2014Unimed Pharmaceuticals, LlcTestosterone gel and method of use
US20120046702 *3 nov. 201123 févr. 2012Peter GibsonApparatus for delivery of pharmaceuticals to the cochlea
USRE3795028 mars 200031 déc. 2002Atrix LaboratoriesBiogradable in-situ forming implants and methods of producing the same
DE2940146A1 *3 oct. 197930 avr. 1980Stolle Res & DevMikroteilchen zur behandlung der inneren weiblichen geschlechtsorgane und deren verwendung
DE3200763A1 *13 janv. 198225 nov. 1982Mitsui Toatsu ChemicalsArzneimittel-formkoerper
EP0025696A2 *11 sept. 198025 mars 1981Eli Lilly And CompanyControlled release parasiticidal formulations
EP0025697A1 *11 sept. 198025 mars 1981Eli Lilly And CompanyGrowth promotant controlled release formulations and method of treatment
EP0025698A2 *11 sept. 198025 mars 1981Eli Lilly And CompanyControlled release formulations
EP0058481A1 *27 janv. 198225 août 1982Zeneca LimitedContinuous release pharmaceutical compositions
EP0086627A1 *10 févr. 198324 août 1983Unitika Ltd.Anti-cancer device
EP0094513A2 *19 avr. 198323 nov. 1983Akzo GmbHSustained-release body containing an active ingredient
EP0279688A219 févr. 198824 août 1988Genentech, Inc.Methods and compositions for the use of HIV env polypeptides and antibodies thereto
EP0463194A1 *23 juin 19902 janv. 1992Boehringer Ingelheim KgProcess for the preparation of poly(D,L-lactide) and its use as a drug carrier
EP0468199A1 *20 juin 199129 janv. 1992Boehringer Ingelheim KgProcess for the preparation of poly(D,L-lactide) and its use as a drug carrier
EP0773034A1 *27 sept. 198914 mai 1997Atrix Laboratories, Inc.Biodegradable in-situ forming implants
EP1666499A26 mai 19977 juin 2006Genentech, Inc.Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
EP2050762A28 mars 199922 avr. 2009Genentech, Inc.Novel polypeptides and nucleic acids encoding the same
EP2138162A21 juil. 200530 déc. 2009Gilead Sciences, Inc.Gel comprising tenofovir or tenofovir disoproxil
EP2138163A21 juil. 200530 déc. 2009Gilead Sciences, Inc.Suppository formulations comprising tenofovir or tenofovir disoproxil
EP2163562A221 juin 200617 mars 2010XOMA Technology Ltd.IL-1beta binding antibodies and fragments thereof
EP2283812A21 juil. 200516 févr. 2011Gilead Sciences, Inc.Topical antiviral formulations
EP2314623A121 juin 200627 avr. 2011XOMA Technology Ltd.IL-1beta binding antibodies and fragments thereof
EP2336322A16 mai 199722 juin 2011Genentech, Inc.Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
EP2371400A213 janv. 20095 oct. 2011Dunn Research & Consulting, LlcLow viscosity liquid polymeric delivery system
EP2546358A115 juil. 201116 janv. 2013Laboratorios Del. Dr. Esteve, S.A.Methods and reagents for efficient control of HIV progression
WO1988000817A1 *4 août 198711 févr. 1988William M KortumImmunological and resistant response in mammary glands
WO1990003768A1 *27 sept. 198919 avr. 1990Southern Res InstBiodegradable in-situ forming implants
WO1994023698A1 *5 avr. 199427 oct. 1994Cambridge Scient IncMethod for making a bioerodible material for the sustained release of a medicament and the material made from the method
WO1994023699A1 *19 avr. 199427 oct. 1994Medisorb Technologies InternatLong-acting treatment by slow-release delivery of antisense oligodeoxyribonucleotides from biodegradable microparticles
WO1995006415A126 août 19949 mars 1995Baylor College MedicineSenescent cell-derived inhibitors of dna synthesis
WO1999017708A12 oct. 199815 avr. 1999Boston Scient CorpGastro-intestinal tube with dissolvable support bolster
WO2001019178A131 août 200022 mars 2001Bertling WolfMethod for marking an animal and products derived therefrom
WO2009086003A118 déc. 20089 juil. 2009Xoma Technology LtdMethods for the treatment of gout
WO2010144797A211 juin 201016 déc. 2010Vaccine Technologies, IncorporatedInfluenza vaccines with enhanced immunogenicity and uses thereof
WO2011067302A11 déc. 20109 juin 2011Seprox Biotech, S.L.Topical use of hydroxytyrosol and derivatives for the prevention of hiv infection
WO2011156594A29 juin 201115 déc. 2011Vaccine Technologies, IncorporatedTherapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
WO2013096516A119 déc. 201227 juin 2013Xoma Technology Ltd.Methods for treating acne
Classifications
Classification aux États-Unis424/477, 424/482, 424/473, 424/444, 424/426, 514/177, 424/469
Classification internationaleA61K9/70, A61K9/20, A61K9/16, A61K9/00
Classification coopérativeA61K9/0024, A61K9/1647, A61K9/2027, A61K9/7007
Classification européenneA61K9/70B, A61K9/00M5D, A61K9/16H6D4, A61K9/20H6B